COGT Reports Full Year 2023 Financial Results and Business Highlights [Yahoo! Finance]
Cogent Biosciences, Inc. (COGT)
Last cogent biosciences, inc. earnings: 11/8 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.cogint.com/investor-relations
Company Research
Source: Yahoo! Finance
Research and Development Expenses : R&D expenses increased to $173.8 million in 2023 from $121.6 million in 2022. General and Administrative Expenses : G&A expenses rose to $34.4 million in 2023, up from $26.2 million in 2022. Net Loss : COGT reported a net loss of $192.4 million for the year ended December 31, 2023, compared to $140.2 million in 2022. Clinical Trials : COGT is actively enrolling in three registration-directed clinical trials for bezuclastinib, with top-line results expected in 2025. Fundraising : Completed a $225 million oversubscribed private investment in public equity (PIPE) in February 2024. Warning! GuruFocus has detected 1 Warning Sign with COGT. On February 26, 2024, Cogent Biosciences Inc ( NASDAQ:COGT ) released its 8-K filing , detailing its financial results for the fourth quarter and full year of 2023. The biotechnology company, known for its focus on developing precision therapies for genetically defined diseases, has reported significant pr
Show less
Read more
Impact Snapshot
Event Time:
COGT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
COGT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
COGT alerts
High impacting Cogent Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
COGT
News
- SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Cogent Biosciences, Inc. (NASDAQ: COGT)PR Newswire
- Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor [Yahoo! Finance]Yahoo! Finance
- Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 InhibitorGlobeNewswire
- Cogent Biosciences, Inc. (NASDAQ: COGT) had its "outperform" rating re-affirmed by analysts at Leerink Partnrs.MarketBeat
- Cogent Biosciences, Inc. (NASDAQ: COGT) had its price target raised by analysts at JPMorgan Chase & Co. from $18.00 to $20.00. They now have an "overweight" rating on the stock.MarketBeat
COGT
Earnings
- 8/8/23 - Miss
COGT
Sec Filings
- 4/23/24 - Form ARS
- 4/23/24 - Form DEFA14A
- 4/23/24 - Form DEF
- COGT's page on the SEC website